3SBio Inc (1530) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
40
About the Report
About the Report
Summary
3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large markets with significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology and other therapeutic areas. the company's products are distributed to hospitals, clinics and dialysis centers across China. The company's products are approved for sale in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, Philippines, Paraguay, Thailand and Trinidad and Tobago. 3SBio is headquartered in Shenyang, China.
3SBio Inc (1530)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
3SBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Venture Financing 13
Refuge Biotech Raises USD25 Million in Series B Financing 13
Private Equity 15
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Partnerships 17
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
Licensing Agreements 23
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
Equity Offering 29
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
Acquisition 31
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc-Key Competitors 35
3SBio Inc-Key Employees 36
3SBio Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Corporate Communications 39
Jan 09, 2017: 3SBio Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Figure
List of Figures
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
3SBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Refuge Biotech Raises USD25 Million in Series B Financing 13
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc, Key Competitors 35
3SBio Inc, Key Employees 36
3SBio Inc, Other Locations 37
3SBio Inc, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.